Prosecution Insights
Last updated: April 19, 2026
Application No. 17/991,448

MODULATORS OF HEMOGLOBIN

Final Rejection §DP
Filed
Nov 21, 2022
Examiner
JARRELL, NOBLE E
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Global Blood Therapeutics Inc.
OA Round
2 (Final)
81%
Grant Probability
Favorable
3-4
OA Rounds
3y 2m
To Grant
90%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allow Rate
824 granted / 1014 resolved
+21.3% vs TC avg
Moderate +9% lift
Without
With
+8.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
56 currently pending
Career history
1070
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
16.0%
-24.0% vs TC avg
§102
20.9%
-19.1% vs TC avg
§112
41.9%
+1.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1014 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment Claims 21-27 are examined on the merits. The amendment filed 2025 June 20 overcomes the non-statutory double patenting rejections against US 10683285 and US 11548880 are overcome because terminal disclaimers filed 2025 June 20 were approved 2025 June 26. The non-statutory double patenting rejections against US 11851424 and 18/717181 are maintained for the reasons below stated in the action below. As stated in the non-final rejection of 2025 March 20, the effective filing date of the examined application is 20 March 2019 based on provisional application 62 / 821314 (specification, page 2, paragraph [0007]). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 21-27 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 and 16-19 of U.S. Patent No. 11851424. Although the claims at issue are not identical, they are not patentably distinct from each other for the following reasons: the same compound is claimed in claims 1-5 of US 11851424; and the methods recited in claims 16-19 of US 11851424 are the same methods recited in examined claims 21-27. PNG media_image1.png 568 328 media_image1.png Greyscale PNG media_image2.png 170 326 media_image2.png Greyscale Claims 23-27 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3, 5, 30, 49, 56, 63, 68, 69, 128-131, and 135-141 of copending Application No. 18/717181 (reference application; US PGPub 20250041312). Although the claims at issue are not identical, they are not patentably distinct from each other because the cited claims of copending application 18/717181 recite the same compound and method encompassed or recited in examined claims 23-27. PNG media_image3.png 458 326 media_image3.png Greyscale This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Arguments The rejection against US 11851424 is maintained because examined claim 21 encompasses any form of the recited compound, including a crystalline compound thereof. Consequently, a compound of claim 1 of US 11851424 is encompassed by examined claim 1 as are the recited methods. When the rejection against US 11851424 is overcome, the provisional double patenting rejection against application 18/171181 will be dropped because the application was filed after the effective filing date of the examined application. Allowable Subject Matter Claims 21-27 are not allowed. The following is a statement of reasons for the indication of allowable subject matter: Parent (WO 2022241278, published 17 November 2022) describes compound 1 (page 2). Although this compound is identical to the compound recited in claims 21-27, this reference is not prior art because it was published after the effective filing date of the examined application. PNG media_image4.png 238 186 media_image4.png Greyscale THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE E JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached 9:00 AM to 5:00 PM. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NOBLE E JARRELL whose telephone number is (571)272-9077. The examiner can normally be reached 9:00 AM to 5:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NOBLE E JARRELL/Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Nov 21, 2022
Application Filed
Feb 10, 2023
Response after Non-Final Action
Mar 12, 2025
Non-Final Rejection — §DP
Jun 20, 2025
Response Filed
Sep 30, 2025
Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595235
PROCESS FOR PRODUCING 4,5-DIHYDRO-1H-PYRAZOLES AND INTERMEDIATES
2y 5m to grant Granted Apr 07, 2026
Patent 12595265
INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE
2y 5m to grant Granted Apr 07, 2026
Patent 12588410
ORGANIC ELECTROLUMINESCENT MATERIAL AND METHOD PREPARING THE SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12570660
PROCESS FOR THE PREPARATION OF A PYRIMIDINO-DIAZEPINE DERIVATIVE
2y 5m to grant Granted Mar 10, 2026
Patent 12570626
DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
81%
Grant Probability
90%
With Interview (+8.7%)
3y 2m
Median Time to Grant
Moderate
PTA Risk
Based on 1014 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month